Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

3309 - Heat Shock Protein 90 chaperones and Protein Kinase D3 regulates androgen-independent prostate cancer development


28 Sep 2019


Poster Display session 1


Pathology/Molecular Biology

Tumour Site

Prostate Cancer


Attila Varga


Annals of Oncology (2019) 30 (suppl_5): v797-v815. 10.1093/annonc/mdz269


A. Varga1, B. Bátai2, P. Gyulavári1, M.T. Nguyen3, C. Sőti3, T. Vántus3

Author affiliations

  • 1 Mta Se Pathobiochemistry Research Group, Semmelweis University, 1094 - Budapest/HU
  • 2 Mta-se Momentum Molecular Oncohematology Research Group, 1st Department Of Pathology And Experimental Cancer Research, Semmelweis University, 1085 - Budapest/HU
  • 3 Department Of Medical Chemistry, Molecular Biology And Pathobiochemistry, Semmelweis University, 1094 - Budapest/HU


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3309


Prostate cancer is the second leading cause of cancer related deaths in men worldwide. Heat Shock Protein 90 (Hsp90) is expressed in tumour cells at high levels – 3-5% of total proteins – and regulates the function of oncogenes and other tumour related proteins. Protein kinase D3 (PKD3) has a proven role in the progression of androgen-independent prostate cancer. In the present study we set out to explore the impact of Hsp90 and PKD3, respectively, on prostate cancer growth and their potential interaction.


We employed the DU145 and PC3 well-characterized androgen-independent prostate cancer cell lines. Cell viability was determined by Trypan Blue exclusion cell counting. Apoptosis analysis was performed by flow cytometry after AnnexinV and propidium-iodide co-staining. Protein levels were detected by western blot and protein-protein interactions were investigated by co-immunoprecipitation.


We found that the clinically used Hsp90 inhibitor ganetespib induced apoptosis and significantly reduced the viability of the androgen-independent DU145 and PC3 cell lines. The pan-PKD inhibitor CRT0066101 also decreased cell viability of the prostate cancer cells in a dose-dependent manner. Further, we demonstrated that ganetespib reduced PKD3 protein level in a concentration-dependent manner and induced its proteasomal degradation. Finally, a co-immunoprecipitation study revealed a physical connection between PKD3 and Hsp90.


We identified and confirmed an Hsp90-PKD3 chaperone client interaction, which may be important in prostate cancer cell survival. Further studies are under way to characterize the biological significance of our findings. Our results contribute to better understand the pathological signalling of androgen-independent prostate cancer cells and to find novel treatment strategies.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

MTA-SE Pathobiochemistry Research Group.


National Research, Development and Innovation Office - Hungary.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.